|
(1) Intestinal Organoid Models for APC LOH
|
5R21CA208638-02
|
$192,406
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221704-01A1
|
$1,050,067
|
OGUNWOBI, OLORUNSEUN
|
HUNTER COLLEGE
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
3R01CA227473-01S1
|
$293,469
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia
|
1UG3CA233282-01
|
$770,562
|
DIGNAN, MARK
|
UNIVERSITY OF KENTUCKY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
1R01CA216290-01
|
$338,903
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
3R01CA206025-03S1
|
$52,355
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
|
1R01CA231267-01
|
$460,814
|
FEHRENBACHER, JILL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
|
1R01CA219637-01A1
|
$281,441
|
DAMAJ, M IMAD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
3R01CA205967-03S2
|
$230,366
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
1R01CA208735-01A1
|
$729,393
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQ9) A NOVEL MECHANISM OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY AND POTENTIAL TREATMENT
|
7R01CA208765-02
|
$356,362
|
YANG, QING
|
UNIVERSITY OF TEXAS MED BR GALVESTON
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
5R21CA205437-03
|
$168,236
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-04
|
$552,684
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA1) The antipsychotic thioridazine protects against medulloblastoma (MB): volu
|
5R01CA185039-04
|
$373,436
|
JAN, LILY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
5R01CA184820-04
|
$386,650
|
DUBOIS, RAYMOND
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
(PQB-4) Single cell analysis strategy for monitoring drug responses of tumors
|
5R01CA190122-04
|
$571,080
|
TIAN, QIANG
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
5R01CA185457-04
|
$640,378
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2 Cherokee Nation/Stephenson Cancer Center Collaborative on Cancer Disparities
|
3P20CA202923-04S1
|
$32,990
|
KHAN, SOHAIL
|
CHEROKEE NATION
|
|
1/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch
|
2U54CA132383-11
|
$1,161,316
|
UNGUEZ, GRACIELA
|
NEW MEXICO STATE UNIVERSITY LAS CRUCES
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-08
|
$1,258,708
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192973-04
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research
|
3U54CA156734-08S1
|
$64,152
|
COLON-CARMONA, ADAN
|
UNIVERSITY OF MASSACHUSETTS BOSTON
|
|
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221705-01A1
|
$1,671,024
|
MA, GRACE
|
TEMPLE UNIV OF THE COMMONWEALTH
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-03S1
|
$63,140
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-04S1
|
$62,420
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|